Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2025-06-22 DOI:10.1080/10428194.2025.2519921

Rudra Narayan Swain, Smita Pattanaik, Arihant Jain, Sarthak Wadhera, Charanpreet Singh, Alka Khadwal, Pankaj Malhotra, Gaurav Prakash

引用次数: 0

查看原文本刊更多论文

在新诊断的急性髓系白血病患者中，尽管较低的药代动力学暴露，50 mg venetoclax与泊沙康唑与400 mg venetoclax的反应率比较：少就足够了。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor